Eli Lilly and Company

Washington University

Other

National Institutes of Health, a Component of the US Dept. of Health & Human Services

University of Miami

Steven Marc Paul

Kelly R Bales

David Michael Holtzman

Ronald DeMattos

Henry U Bryant

Maximiliano Vasquez

Naoya Tsurushita

Binhui Ni

David J Cummins

Xin Wu

Michele Annette Glinn

Barbara Cordell

Gary Dennis Tollefson

Qiang Xu

Bennett C Laguzza

John Harrison Heiligenstein

Edward I Ginns

Janice A Egeland

Asha Naidu

Mary Patricia Knadler

A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A&#x3b2;, A&#x3b2;, their ratio, or their rate of entry following administration of antibodies that sequester A&#x3b2;. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.

Assay method for Alzheimer's disease

A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A&#x3b2; peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A&#x3b2;.

Humanized antibodies that sequester amyloid beta peptide

Assay method for alzheimer's disease

A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A&#x3b2; peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13&#x2013;28 of the amyloid beta peptide A&#x3b2;.

Humanized antibodies that sequester abeta peptide

Chromosomal regions comprising loci associated with susceptibility and resistance to bipolar affective disorder have been identified. Methods and compositions are provided for determining the contribution of these chromosomal regions to bipolar affective disorder in an affected family, for determining in an affected family a genotype associated with increased or decreased susceptibility or resistance to bipolar illness, and for assessing an increased or decreased risk of developing bipolar illness for a tested individual from an affected family.

Susceptability and resistance genes for bipolar affective disorder

The present invention provides a method of assaying for and arresting, preventing and/or reversing the impairment of central and peripheral nervous system function comprising reducing &bgr;-amyloid plaque burden by the administration of compounds that reduce apoE expression. The compounds used in the method of the invention may be: 1) inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase; 2) inhibitors of cholesterol biosynthesis; 3) inhibitors of protein isoprenylation, specifically geranylgeranylation; and/or 4) inhibitors of NF-&kgr;B activation or function. Assays for compounds with inhibit apoE expression from microglial cells are also disclosed.

Assay to identify compounds that alter apolipoprotein E expression

The present invention is directed to increasing levels of acetylcholine by the administration of 2-aryl-3-aroylbenzo&lsqb;b&rsqb;thiophenes.

Methods for increasing levels of acetylcholine

The current invention relates to a method for increasing levels of acetylcholine comprising administering to a mammal in need thereof, an effective amount of a compound of formula (I), and optionally an AChE inhibitor.

The invention is a device for storing, dispensing and recycling a suspension of regenerating microorganism. The device provides an opening allowing a user to remove a portion of the suspension. The device defines a first area for receipt of new suspension and a second area for dispensing of such suspension for use. Preferably, an angled plate in the interior of the device forms a passage through which the suspension passes towards the dispensing opening. After use, the used suspension is recycled by again pouring the used suspension back into the device through a screen cover. The device allows a user to continue to reuse suspension from the device in that the device recycles such suspension in a manner that allows the microorganism to regenerate as it travels through the device towards the dispensing opening.

Device for storing, dispensing and recycling a cleaning suspension including a regenerating microorganism absorbent suspension

The present invention provides a method of treating depression, mood swings, or Alzheimer's disease in a patient in need of such treatment by administering a selective estrogen receptor modulating compound of the formula ##STR1## in which R.sup.1 and R.sup.2 are independently hydroxy and alkoxy of one to four carbon atoms; and R.sup.3 and R.sup.4 are independently methyl or ethyl, or R.sup.3 and R.sup.4, taken together with the nitrogen atom to which they are attached, form a pyrrolidino, methyl-pyrrolidino, dimethylpyrrolidino, piperidino, morpholino, or hexamethyleneimino ring.

Treatment of central nervous system disorders with selective estrogen

A group of propanamines, norepinephrine uptake inhibitors, are used to treat attention-deficit/hyperactivity disorder.

Treatment of attention-deficit/hyperactivity disorder

This invention describes a novel human brain Na.sup.+ -dependent inorganic phosphate cotransporter, designated the hBNPI protein. This invention also encompasses nucleic acids encoding this protein, or a fragment thereof, as well as methods employing this protein and the nucleic acid compounds.

Growing community of inventors

Carmel, IN, United States of America

Steven Marc Paul